Nucleotides

CleanCap® Reagent M6 [CleanCap m6AG (3’ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNAs produced by legacy capping methods. The addition of a methyl group on position 6 of the first adenosine (m6A) may further increase protein expression relative to CleanCap AG or CleanCap AG (3’OMe). It has been hypothesized that the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)​ CleanCap M6 uses the same 5’ AG initiation sequence as CleanCap AG and CleanCap AG (3’OMe). ​ CleanCap has been shown to provide > 95% capping efficiency and typical crude yields of 4 mg to 5 mg per mL of transcription.​ CleanCap M6 can be used in conjunction with wildtype bases or TriLink’s catalog of modified NTPs, such as N1-Methylpseudouridine-5’-Triphosphate (N-1081), Pseudouridine-5’-Tr

CleanCap® Reagent M6 [CleanCap m6AG (3’ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNAs produced by legacy capping methods. The addition of a methyl group on position 6 of the first adenosine (m6A) may further increase protein expression relative to CleanCap AG or CleanCap AG (3’OMe). It has been hypothesized that the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)​ CleanCap M6 uses the same 5’ AG initiation sequence as CleanCap AG and CleanCap AG (3’OMe). ​ CleanCap has been shown to provide > 95% capping efficiency and typical crude yields of 4 mg to 5 mg per mL of transcription.​ CleanCap M6 can be used in conjunction with wildtype bases or TriLink’s catalog of modified NTPs, such as N1-Methylpseudouridine-5’-Triphosphate (N-1081), Pseudouridine-5’-Tr

CleanCap® Reagent M6 [CleanCap m6AG (3’ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNAs produced by legacy capping methods. The addition of a methyl group on position 6 of the first adenosine (m6A) may further increase protein expression relative to CleanCap AG or CleanCap AG (3’OMe). It has been hypothesized that the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)​ CleanCap M6 uses the same 5’ AG initiation sequence as CleanCap AG and CleanCap AG (3’OMe). ​ CleanCap has been shown to provide > 95% capping efficiency and typical crude yields of 4 mg to 5 mg per mL of transcription.​ CleanCap M6 can be used in conjunction with wildtype bases or TriLink’s catalog of modified NTPs, such as N1-Methylpseudouridine-5’-Triphosphate (N-1081), Pseudouridine-5’-Tr

DMTr-TNA A(Bz)-amidite is phosphoramidite monomer that can be polymerized to create DNA oligonucleotides

DMTr-TNA C(Bz)-amidite is a phosphoramidite monomer comprised of a cytidine modified by the addition of a benzoyl functional group, and it can be used to make oligonucleotides.

DMTr-TNA-U amidite is a uradine phosphoramidite monomer used in RNA synthesis.

0